The Tumor Suppressive Effects of HPP1 Are Mediated Through JAK-STAT-Interferon Signaling Pathways

Jonathan M Hernandez1, Abul Elahi1, Whalen Clark1

  • 11 Department of Gastrointestinal Oncology, Moffitt Cancer Center , Tampa, Florida.

DNA and Cell Biology
|June 11, 2015
PubMed

Insights

HPP1, a tumor suppressor, uses STAT2 activation to inhibit colon cancer growth. This involves Janus kinase-signal transducer and activator of transcription-interferon signaling, enhancing sensitivity to interferon-alpha therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • HPP1 is a novel tumor suppressive epidermal growth factor (EGF)-like ligand.
  • HPP1 function is linked to signal transducer and activator of transcription (STAT) activation, particularly STAT1.
  • The specific role of STAT2 in HPP1's tumor suppressive activity requires elucidation.

Purpose of the Study:

  • To delineate the components of Janus kinase (JAK)-STAT-interferon (IFN) signaling associated with HPP1's biological effects.
  • To investigate the necessity of STAT2 for HPP1-mediated growth suppression in colon cancer cells.

Main Methods:

  • Stable HPP1-HCT116 transfectants were generated for expression analyses (PCR/Western blotting).
  • Small interfering RNA (siRNA) was used for gene knockdown studies.
  • Assays included proliferation, cell cycle distribution, anchorage-independent growth, reporter assays, fluorescent microscopy, and chromatin immunoprecipitation (ChIP).

Main Results:

  • HPP1 overexpression upregulated total and activated STAT2, along with JAK1 and JAK2 activation.
  • HPP1 increased STAT1:STAT1 and STAT1:STAT2 dimer formation and nuclear translocation.
  • Activated STAT1 and STAT2 bound to interferon-signaling regulatory elements of target genes (PKR, IFI44, OAS1).
  • STAT2 knockdown partially abrogated HPP1's growth suppressive effects.
  • HPP1 transfectants showed increased sensitivity to interferon-alpha (IFN-α).

Conclusions:

  • STAT2 is essential for HPP1-associated growth suppression in colon cancer.
  • HPP1 mediates tumor suppression through STAT2 activation of IFN-α pathways.
  • Understanding HPP1's role is crucial for developing targeted therapies against oncogenic erbB proteins.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K